Literature DB >> 18474224

The IL-6 family of cytokines modulates STAT3 activation by desumoylation of PML through SENP1 induction.

Norihiko Ohbayashi1, Shiho Kawakami, Ryuta Muromoto, Sumihito Togi, Osamu Ikeda, Shinya Kamitani, Yuichi Sekine, Tsutomu Honjoh, Tadashi Matsuda.   

Abstract

Post-translational modification by small ubiquitin-like modifier (SUMO) plays an important role in the regulation of different signaling pathways and is involved in the formation of promyelocytic leukemia (PML) protein nuclear bodies following sumoylation of PML. In the present study, we found that IL-6 induces desumoylation of PML and dissociation between PML and SUMO1 in hepatoma cells. We also found that IL-6 induces mRNA expression of SENP1, a member of the SUMO-specific protease family. Furthermore, wild-type SENP1 but not an inactive SENP1 mutant restored the PML-mediated suppression of STAT3 activation. These results indicate that the IL-6 family of cytokines modulates STAT3 activation by desumoylation and inactivation PML through SENP1 induction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474224     DOI: 10.1016/j.bbrc.2008.04.179

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  SUMOylation and De-SUMOylation: wrestling with life's processes.

Authors:  Edward T H Yeh
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

2.  SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.

Authors:  Yan Han; Chao Huang; Xuxu Sun; Binggang Xiang; Ming Wang; Edward T H Yeh; Yuying Chen; Hui Li; Guiying Shi; Hui Cang; Yueping Sun; Jian Wang; Wei Wang; Fei Gao; Jing Yi
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

3.  Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.

Authors:  Isha Sengupta; Dipanwita Das; Shivaram Prasad Singh; Runu Chakravarty; Chandrima Das
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

4.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

5.  Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.

Authors:  Anne Sofie Brems-Eskildsen; Karsten Zieger; Helle Toldbod; Cherie Holcomb; Russell Higuchi; Francisco Mansilla; Pia P Munksgaard; Michael Borre; Torben F Ørntoft; Lars Dyrskjøt
Journal:  BMC Cancer       Date:  2010-11-24       Impact factor: 4.430

6.  Regulation of the tumor suppressor PML by sequential post-translational modifications.

Authors:  M Lienhard Schmitz; Inna Grishina
Journal:  Front Oncol       Date:  2012-12-31       Impact factor: 6.244

7.  The herpesvirus associated ubiquitin specific protease, USP7, is a negative regulator of PML proteins and PML nuclear bodies.

Authors:  Feroz Sarkari; Xueqi Wang; Tin Nguyen; Lori Frappier
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

Review 8.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

9.  Post-translational modifications of PML: consequences and implications.

Authors:  Xiwen Cheng; Hung-Ying Kao
Journal:  Front Oncol       Date:  2013-01-04       Impact factor: 6.244

Review 10.  Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Int J Biol Sci       Date:  2009-05-22       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.